Exponent EXPO
- Market cap
- $3.7B
- PE
- 34.7×
- 10y median 46.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.8×
- EV/EBIT
- 29.0×
- Revenue, 12 months
- $632.5M
- +13% on a year ago
- Net margin
- 17.7%
- Free cash flow yield
- 2.9%
Exponent trades at 34.7× trailing earnings, cheaper than 85% of the last ten years. Revenue was $632.5M over the last twelve months, up 13% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $133.3M+5% | $122.9M−4% | $144.9M+3% | $140.5M+0% | $136.3M+2% | $136.8M+11% | $145.5M+0% | $142M+1% | $147.1M+8% | $147.4M+8% | $166.3M+14% | $171.6M+21% | |
| SG&A | $6M−11% | $5.9M−15% | $5.6M−4% | $6M−9% | $5.3M−12% | $5.7M−3% | $5M−11% | $6.1M+2% | $7.7M+44% | $6.7M+17% | $6.2M+24% | $7.4M+21% |
| $33.9M−8% | $18.4M−17% | $30.7M+6% | $35.7M+20% | $25.8M−24% | $27.3M+48% | $44.4M+45% | $17.2M−52% | $29M+12% | $29.1M+7% | $41.4M−7% | $28M+63% | |
| Pre-tax income | $34M+2% | $30.1M−1% | $40.4M+14% | $39.7M+10% | $35.9M+6% | $31.3M+4% | $37.8M−7% | $36.8M−7% | $38.6M+8% | $34.1M+9% | $42.3M+12% | $40.8M+11% |
| $9.5M+5% | $9.2M+15% | $10.3M+60% | $10.5M−1% | $9.9M+4% | $7.7M−16% | $11.1M+8% | $10.3M−2% | $10.6M+7% | $9.3M+21% | $12.8M+15% | $11.4M+11% | |
| Net income | $24.5M+0% | $20.9M−7% | $30.1M+4% | $29.2M+14% | $26M+6% | $23.6M+13% | $26.6M−12% | $26.6M−9% | $28M+8% | $24.8M+5% | $29.6M+11% | $29.4M+11% |
| $0.48+2% | $0.41−7% | $0.59+5% | $0.57+14% | $0.50+4% | $0.46+12% | $0.52−12% | $0.52−9% | $0.55+10% | $0.49+7% | $0.59+14% | $0.60+15% | |
| 51.6M−1% | 51.5M−0% | 51.4M−1% | 51.5M−0% | 51.6M+0% | 51.7M+0% | 51.6M+0% | 51.5M+0% | 51.2M−1% | 50.6M−2% | 50.1M−3% | 49M−5% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY21 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Consulting Services nearest Exponent's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EXPOExponent | $3.7B | 34.7× | 46.6× | 5.8× | +13% | 17.7% | |
| FCNFTI Consulting | $4.3B | 19.0× | 22.0× | 1.1× | +7% | 6.4% | |
| HURNHuron Consulting | $3.1B | 29.3× | 25.9× | 1.7× | +14% | 6.4% | |
| ASTHAstrana Health | $2.1B | 45.7× | 35.1× | 0.5× | +59% | 1.1% | |
| GGenpact LTD | $6.9B | 12.1× | 21.6× | 1.3× | +7% | 11.1% | |
| ICFIICF International | $1.7B | 19.5× | 23.2× | 0.9× | −8% | 4.9% | |
| BAHBooz Allen Hamilton | $9.4B | 12.3× | 21.5× | 0.8× | −7% | 7.0% | |
| BWMNBowman Consulting | $742.5M | 107× | 106× | 1.4× | +14% | 1.4% | |
| EFXEquifax | $21.4B | 32.0× | 41.1× | 3.3× | +10% | 10.7% | |
| Peer median | $3.7B | 24.4× | 24.5× | 1.2× | +9% | 6.4% |
Investors who own it
Investors we follow who held Exponent at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Exponent
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 17Consulting Services stocks with the highest profit margins
- #5of 17Consulting Services stocks with the fastest revenue growth
- #3of 10Consulting Services stocks cheapest against their own PE history
- #7of 12Consulting Services stocks with the fastest earnings growth
- #10of 13Consulting Services stocks with the lowest PE ratio
Its groups
About
- Industry
- Consulting Services
- Sector
- Industrials
Valuation data, not investment advice. Prices as of .